Medtronic to acquire Contego Medical in $380 million deal
Medtronic announced on Nov. 16, 2026, its intent to acquire privately held Contego Medical in a deal valued at $380 million, converting an existing distribution partnership into full ownership.
The acquisition builds on an exclusive US distribution agreement between the two companies, first announced in January 2025. It advances Medtronic’s strategy of targeted investments to strengthen its core franchises.
The transaction still awaits customary closing conditions, and potential payments post-acquisition remain part of its value.
The planned acquisition includes the recently FDA-approved Neuroguard IEP Direct System, Medtronic said. The company called it the first and only transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP) in addition to flow reversal.
In the prospective, multicenter PERFORMANCE III study, the system showed zero strokes, zero neurological deaths, zero cranial nerve injuries and zero myocardial infarctions at 30 days. This data likely underpins Medtronic’s aim to lead in carotid revascularization.
The deal also includes Contego’s Excipio thrombectomy devices, which complement Medtronic’s Liberant thrombectomy system in treating peripheral vascular disease.
“With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease,” said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health.
“Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease,” said Linnea Burman, senior vice president and president of Medtronic Neurovascular.
Carotid artery disease context
Carotid artery disease occurs when the carotid arteries, which supply the brain, become narrowed or blocked. Plaque can rupture or embolize and lead to a stroke, accounting for about 20% of ischemic strokes.
Embolic debris released during carotid revascularization can contribute to procedural stroke risk. The Neuroguard IEP Direct System is designed to address this specific risk profile.
Medtronic plc is a healthcare technology company headquartered in Galway, Ireland, with a team of 90,000+ people across more than 150 countries. Its technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools and patient monitoring systems.
Contego Medical’s investors include Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures and Amzak Health.
What to watch
For MDT holders, the financial effect appears modest, with Medtronic projecting minimal adjusted EPS dilution in FY27 and FY28, then neutral to accretive results. Open points include the size and conditions of potential payments post-acquisition and completion of customary closing conditions.
Investors should watch the third quarter of Medtronic’s fiscal year, when the Contego Medical acquisition is expected to close. Closing depends on customary conditions and brings Contego’s devices into Medtronic.
Management may also provide updates on the Contego acquisition and its expected EPS effect during Medtronic’s quarterly results report on Nov. 24, 2026.
